Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells.

There is evidence to suggest that elevated plasma levels of lipoprotein (a) [Lp(a)] represent a risk factor for the development of atherosclerotic vascular disease, but the mechanism by which this lipoprotein localizes to involved vessels is only partially understood. In view of studies suggesting a link between inflammation and atherosclerosis and our previous finding that leukocyte defensin modulates the interaction of plasminogen and tissue-type plasminogen activator with cultured human endothelial cells, we examined the effect of this peptide on the binding of Lp(a) to cultured vascular endothelium and vascular smooth muscle cells. Defensin increased the binding of Lp(a) to endothelial cells approximately fourfold and to smooth muscle cells approximately sixfold. Defensin caused a comparable increase in the amount of Lp(a) internalized by each cell type, but Lp(a) internalized as a consequence of defensin being present was not degraded, resulting in a marked increase in the total amount of cell-associated lipoprotein. Abundant defensin was found in endothelium and in intimal smooth muscle cells of atherosclerotic human cerebral arteries, regions also invested with Lp(a). These studies suggest that defensin released from activated or senescent neutrophils may contribute to the localization and persistence of Lp(a) in human vessels and thereby predispose to the development of atherosclerosis.

[1]  T. Ganz,et al.  Defensin Modulates Tissue-type Plasminogen Activator and Plasminogen Binding to Fibrin and Endothelial Cells* , 1996, The Journal of Biological Chemistry.

[2]  R. Rosenson Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. , 1996, Archives of internal medicine.

[3]  H. Becher,et al.  The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. , 1996, Thrombosis research.

[4]  E. Feskens,et al.  White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[5]  G. Heiss,et al.  Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[6]  B. Bouma,et al.  Effect of Lipoprotein(a) and LDL on Plasminogen Binding to Extracellular Matrix and on Matrix-dependent Plasminogen Activation by Tissue Plasminogen Activator , 1996, Thrombosis and Haemostasis.

[7]  S. Biro,et al.  Lipoprotein(a) stimulates the proliferation of cultured human arterial smooth muscle cells through two pathways , 1995, FEBS letters.

[8]  D. Rader,et al.  Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. , 1995, The American journal of pathology.

[9]  A. Stead,et al.  Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. , 1995, Stroke.

[10]  M. Callow,et al.  Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). , 1995, The Journal of clinical investigation.

[11]  P. Ridker,et al.  Plasma concentration of lipoprotein(a) and the risk of future stroke. , 1995, JAMA.

[12]  A. Higazi,et al.  Identification of an Inhibitor of Tissue-type Plasminogen Activator-mediated Fibrinolysis in Human Neutrophils , 1995, The Journal of Biological Chemistry.

[13]  D. Rader,et al.  The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. , 1995, The Journal of clinical investigation.

[14]  R. Lawn,et al.  Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice , 1994, Nature.

[15]  D. Rader,et al.  Quantitation of Plasma Apolipoproteins in the Primary and Secondary Prevention of Coronary Artery Disease , 1994, Annals of Internal Medicine.

[16]  P. Harpel,et al.  Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. , 1994, Biochemistry.

[17]  T. Ganz,et al.  Defensins: a family of antimicrobial and cytotoxic peptides. , 1994, Toxicology.

[18]  A. Folsom,et al.  Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1993, The American journal of medicine.

[19]  A. Gown,et al.  Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[20]  P. Harpel,et al.  Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator. , 1993, Biochemistry.

[21]  T. Ganz,et al.  Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. , 1993, The Journal of laboratory and clinical medicine.

[22]  W. März,et al.  Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor‐related protein/α2‐macroglobulin receptor , 1993, FEBS letters.

[23]  D. Cines,et al.  Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. , 1993, The Journal of biological chemistry.

[24]  P. Weissberg,et al.  Proliferation of human smooth muscle cells promoted by lipoprotein(a). , 1993, Science.

[25]  J. Loscalzo,et al.  Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. , 1993, Biochemistry.

[26]  M. Jauhiainen,et al.  Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus , 1993, The Lancet.

[27]  H. Fukushi,et al.  Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. , 1993, The Journal of infectious diseases.

[28]  R. Grimm,et al.  The white blood cell count and risk for coronary heart disease. , 1992, American heart journal.

[29]  D. Siscovick,et al.  Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. , 1992, JAMA.

[30]  V. Tertov,et al.  The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. , 1992, Clinical immunology and immunopathology.

[31]  R. Klein,et al.  Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. , 1992, Metabolism: clinical and experimental.

[32]  M. Ultsch,et al.  Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-A resolution. , 1992, Biochemistry.

[33]  T. Ganz,et al.  An enzyme immunoassay for human defensins. , 1991, Journal of immunological methods.

[34]  J. Huttunen,et al.  Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. , 1991, Atherosclerosis.

[35]  R. Kronmal,et al.  Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[36]  D. Eisenberg,et al.  Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. , 1991, Science.

[37]  A. Salamon,et al.  Immunochemistry of human Lp[a]: characterization of monoclonal antibodies that cross-react strongly with plasminogen. , 1991, Journal of lipid research.

[38]  E. B. Smith,et al.  Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. I. Relation between fibrin and immobilization of apo B-containing lipoprotein. , 1990, Atherosclerosis.

[39]  E. B. Smith,et al.  Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). , 1990, Atherosclerosis.

[40]  R. Hammer,et al.  Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. , 1990, The Journal of clinical investigation.

[41]  S. Surrey,et al.  Biologic and biochemic properties of recombinant platelet factor 4 demonstrate identity with the native protein. , 1990, Blood.

[42]  A. Vaheri,et al.  Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. , 1989, The EMBO journal.

[43]  M. Dietel,et al.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. , 1989, Arteriosclerosis.

[44]  J. Breslow,et al.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis , 1989, Nature.

[45]  A. Scanu,et al.  A potential basis for the thrombotic risks associated with lipoprotein(a) , 1989, Nature.

[46]  M. Selsted,et al.  Determination of the disulfide array in the human defensin HNP-2. A covalently cyclized peptide. , 1989, The Journal of biological chemistry.

[47]  P. Carlsson,et al.  Identification of Apo B‐100 Segments Mediating the Interaction of Low Density Lipoproteins with Arterial Proteoglycans , 1988, Arteriosclerosis.

[48]  E. Chen,et al.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen , 1987, Nature.

[49]  J. Dormandy,et al.  Leukocytes and the risk of ischemic diseases. , 1987, JAMA.

[50]  G. Daggard,et al.  CORONARY ARTERY BYPASS GRAFT FAILURE—AN AUTOIMMUNE PHENOMENON? , 1986, The Lancet.

[51]  J. Neaton,et al.  Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. , 1985, JAMA.

[52]  R I Lehrer,et al.  Primary structures of three human neutrophil defensins. , 1985, The Journal of clinical investigation.

[53]  T. Ganz,et al.  DEFENSINS: NATURAL PEPTIDE ANTIBIOTICS IN HUMAN NEUTROPHILS , 1986 .

[54]  D. Cines,et al.  Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. , 1984, The Journal of clinical investigation.

[55]  J. McDougall,et al.  Viruses in the etiology of atherosclerosis. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Debakey,et al.  CYTOMEGALOVIRUS ANTIGEN WITHIN HUMAN ARTERIAL SMOOTH MUSCLE CELLS , 1983, The Lancet.

[57]  J. Richard,et al.  Leukocyte count, smoking, and myocardial infarction. , 1981, The New England journal of medicine.

[58]  A. Siegelaub,et al.  The leukocyte count as a predictor of myocardial infarction. , 1974, The New England journal of medicine.

[59]  I. Weinbren SPONTANEOUS PERIODIC ŒDEMA: A New Syndrome , 1963 .

[60]  R. Magno,et al.  Coronary heart disease , 1957 .

[61]  T. Ganz,et al.  Neutrophil defensins: purification, characterization, and antimicrobial testing. , 1994, Methods in enzymology.

[62]  R. Nachman,et al.  Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[63]  R J Glynn,et al.  White blood cell count as a predictor of mortality: results over 18 years from the Normative Aging Study. , 1990, Journal of clinical epidemiology.

[64]  R. Breuer,et al.  Book-Review - Contact with the Stars - the Search for Extraterrestrial Life , 1982 .